Clarification needed on the effects of FLACS

Article

More research required to clarify the short- and long-term effects of femtosecond laser-assisted cataract surgery (FLACS) on the corneal endothelium.

The authors of a new review in Current Opinion in Ophthalmology advocate for more research to clarify the short- and long-term effects of femtosecond laser-assisted cataract surgery (FLACS) on the corneal endothelium.

FLACS may reduce endothelial cell loss, they write, but the reduction most likely occurs only in the early postoperative period. Research to date has reached varying conclusions on FLACS’ ability to reduce endothelial cell loss, the authors note. Some studies point to the reduced amount of ultrasound energy required with FLACS. Others show no difference or less cell loss with FLACS than with standard phacoemulsification 1 to 3 months postoperatively. At 6 months, however, some studies have found that cell loss is similar regardless of technique used.

Further, newer advancements in surgical technique or technology - biaxial microincision surgery, the use of ultraviolet light in light-adjustable IOLs, and newer viscous - dispersives, for instance - show cell loss rates that are similar to or better than standard phaco.

“Viscous dispersives may offer equal or increased protection of the corneal endothelium during surgery compared with viscoelastic devices currently in wide use, but further studies are required to support these results,” they add.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.